Bristol-myers Squibb Compnay

Viiv Healthcare UK Limited

Bristol-myers Squibb Holdings Ireland

Denis R St Laurent

Jeffrey Lee Romine

Makonen Belema

Lawrence B Snyder

Omar D Lopez

Van N Nguyen

Nicholas A Meanwell

Fukang Yang

Jason T Goodrich

Andrew Charles Good

David R Langley

Lawrence G Hamann

Edward H Ruediger

Carol Bachand

Rico Lavoie

Alain Martel

Daniel H Deon

Clint A James

Gan Wang

Michael H Serrano-Wu

Yuping Qiu

John A Bender

Ramesh Kakarla

John F Kadow

Paul Michael Scola

Kap-Sun Yeung

Xuejie Yang

Piyasena Hewawasam

B Narasimhulu Naidu

Neelakantan Balasubramanian

Zhong Yang

Ningning Xu

Jayne Kapur

Tao Wang

Zhongxing Zhang

Li-Qiang Sun

Mark George Saulnier

Manoj Patel

Min Ding

Kurt Zimmermann

Katharine A Grant-Young

David Bertil Frennesson

Francis Beaulieu

Min Gao

Michael J Smith

Guo Li

John E Leet

Qi Chen

Julie A Lemm

Karen M Stoffan

Donald R O'Boyle, Ii

Xuhua Karen Du

John A Easter

Bao-Ning Su

Neelakantan Balusubramanian

Byron Hepler Long

Belema Makonen

Ramesh Kakaria

Donald R Ii O'BOYLE

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Compounds useful as immunomodulators

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various pp diseases, including cancer and infectious diseases. (I) 

Substituted isoquionline derivatives as immunomudulators

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. 

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

Growing community of inventors

Newington, CT, United States of America

Denis R St Laurent